60 results
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
5 Dec 23
Departure of Directors or Certain Officers
7:15pm
or its Affiliates or (ii) induce or attempt to induce any customer or investor (in each case, whether former, current or prospective), supplier, licensee … with the relationship between any such customer, investor, supplier, licensee or business relation, on the one hand, and the Company or any of its
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
1 Nov 23
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
4:21pm
and agreements, internal services and operational manuals, methods of conducting business of the Company, suppliers and supplier information … ), supplier, licensee or other business relation of the Company or any of its Affiliates to cease doing business with the Company or such Affiliate
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
practicable, Ocuphire attempts to identify more than one supplier. However, some raw materials are available only from a single source or only one supplier … to successfully produce and market product candidates, if approved, or it could be delayed in doing so. For instance, Ocuphire presently relies on one supplier
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
any placement agent to offer, Common Stock to any person with the intent to influence unlawfully (A) a customer or supplier of the Company to alter
424B5
nh25bviv9fe9o0ak9e
7 Jun 21
Prospectus supplement for primary offering
4:21pm
8-K/A
EX-10.1
90r4oc
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K
EX-10.1
sdsv607uvsz
4 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:48pm
424B5
l96x2
11 Mar 21
Prospectus supplement for primary offering
9:19am
8-K
EX-1.1
z2tcy
11 Mar 21
Entry into a Material Definitive Agreement
8:34am
424B4
x6xohy3 s7w
17 Feb 21
Prospectus supplement with pricing info
7:14am
8-K
EX-14.1
1pkg9j un2
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
424B3
5jn5v7pzw76ok
2 Oct 20
Prospectus supplement
9:25am